Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers

Oligonucleotides

Volumn 17, Issue 3, 2007, Pages 265-274

  Oney, S ^a,b   Nimjee, S M ^a,b   Layzer, J ^a,b   Que Gewirth, N ^a,b   Ginsburg, D ^c   Becker, R C ^a,b   Arepally, G ^b   Sullenger, B A ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; ANTIDOTE OLIGONUCLEOTIDE 6; ANTITHROMBOCYTIC AGENT; APTAMER; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR APTAMER R9.14; VON WILLEBRAND FACTOR APTAMER R9.3;

ARTICLE; COMBINATORIAL CHEMISTRY; CONVERGENT SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; DRUG DESIGN; DRUG EFFECT; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS;

APTAMERS, NUCLEOTIDE; BLOOD PLATELETS; HUMANS; OLIGONUCLEOTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISTOCETIN; SELEX APTAMER TECHNIQUE; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 34648830164     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2007.0089     Document Type: Article

References (30)

1. BECKER, R.C., RUSCONI, C., and SULLENGER, B. (2005). Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application." Thromb. Haemost. 93, 1014-1020.
2. BHATT, D.L. and TOPOL, E.J. (2003). Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov 2, 15-28.
3. CADROY, Y., HANSON, S.R., KELLY, A.B., MARZEC, U.M., EVATT, B.L., KUNICKI, T.J., MONTGOMERY, R.R., and HARKER, L.A. (1994). Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 83, 3218-3224.
4. CAUWENBERGHS, N., MEIRING, N., VAUTERIN, S., VAN WYK, V., LAPRECHT, S., ROODT, J.P., NOVAK, L., HARSFALVI, J., DECKMYN, H., and KOTZE, H.F. (2000). Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. 20, 1347-1353.
5. CHANG, M.C., LIN, H.K., PENG, H.C., and HUANG, T.F. (1998). Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood 91, 1582-1589.
6. DYKE, C.K., STEINHUBL, S.R., KLEIMAN, N.D., CANNON, R.O., ABERLE, L.G., LIN, M., MYLES, S.K., MELLONI, C., HARRINGTON, R.A., ALEXANDER, J.H., BECKER, R.C., and RUSCONI, C.P. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology, a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490-2497.
7. EYETECHSTUDYGROUP. (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative agerelated macular degeneration. Retina 22, 143-152.
8. EYETECHSTUDYGROUP. (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-986.
9. FITZWATER, T., and POLISKY, B. (1996). A SELEX primer. Methods Enzymol. 267, 275-301.
10. HARRISON, P. (2005). Platelet function analysis. Blood Rev. 19, 111-123.
11. HUYNH, T., THEROUX, P., BOGATY, P., NASMITH, J., and SOLYMOSS, S. (2001). Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 103, 3069-3074.
12. JACKSON, S.P., and SCHOENWAELDER, S.M. (2003). Antiplatelet therapy: in search of the 'magic bullet'. Nat. Rev. Drug Discov. 2, 775-789.
13. LAYZER, J. a. S., B.A. (2007). Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and Convergent Selection. Oligonucleotides 17, 1-11.
14. MASON, P.J., JACOBS, A.K., and FREEDMAN, J.E. (2005). Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol. 46, 986-993.
15. MILLER, J.L., THIAM-CISSE, M., and DROUET, L.O. (1991). Reduction in thrombus formation by PG-1 F(ab′)2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arterioscler. Thromb. 11, 1231-1236.
16. NIMJEE, S.M., KEYS, J.R., PITOC, G.A., QUICK, G., RUSCONI, C.P., and SULLENGER, B.A. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol. Ther. 14, 408-115.
17. NIMJEE, S.M., RUSCONI, C.P., HARRINGTON, R.A., and SULLENGER, B.A. (2005a). The potential of aptamers as anticoagulants. Trends Cardiovasc. Med. 15, 41-45.
18. NIMJEE, S.M., RUSCONI, C.P., and SULLENGER, B.A. (2005b). Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 56, 555-583.
19. RUGGERI, Z.M. (2003). Von Willebrand factor, platelets and endothelial cell interactions. J. Thromb. Haemost. 1, 1335-1342.
20. RUGGERI, Z.M., DENT, J.A., and SALDIVAR, E. (1999). Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 94, 172-178.
21. RUSCONI, C.P., ROBERTS, J.D., PITOC, G.A., NIMJEE, S.M., WHITE, R.R., QUICK, G., JR., SCARDINO, E., FAY, W.P., and SULLENGER, B.A. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. 22, 1423-1428.
22. RUSCONI, C.P., SCARDINO, E., LAYZER, J., PITOC, G.A., ORTEL, T.L., MONROE, D., and SULLENGER, B.A. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94.
23. RUSCONI, C.P., YEH, A., LYERLY, H.K., LAWSON, J.H., and SULLENGER, B.A. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb. Haemost. 84, 841-848.
24. SADLER, J.E. (2005). New concepts in von Willebrand disease. Annu. Rev. Med. 56, 173-191.
25. SADLER, J.E. (2005). von Willebrand factor: two sides of a coin. J. Thromb. Haemost. 3, 1702-1709.
26. THOM, T., HAASE, N., ROSAMOND, W., HOWARD, V.J., RUMSFELD, J., MANOLIO, T., ZHENG, Z.J., FLEGAL, K., O'DONNELL, C., KITTNER, S., LLOYD-JONES, D., GOFF, D.C., JR., HONG, Y., ADAMS, R., FRIDAY, G., FURIE, K., GORELICK, P., KISSELA, B., MARLER, J., MEIGS, J., ROGER, V., SIDNEY, S., SORLIE, P., STEINBERGER, J., WASERTHIEL-SMOLLER, S., WILSON, M., and WOLF, P. (2006). "Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee." Circulation 113, e85-151.
27. WONG, I.. and LOHMAN, T.M. (1993). A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc. Natl. Acad. Sci. USA 90, 5428-5432.
28. WU, D., MEIRING, M., KOTZE, H.F., DECKMYN, H., and CAUWENBERGHS, N. (2002a). Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol. 22, 323-328.
29. WU, D., VANHOORELBEKE, K., CAUWENBERGHS, N., MEIRING, M., DEPRAETERE, H., KOTZE, H.F., and DECKMYN, H. (2002). Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 99, 3623-3628.
30. YAMAMOTO, H., VREYS, I., STASSEN, J.M., YOSHIMOTO, R., VERMYLEN, J., and HOYLAERTS, M.F. (1998). Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb. Haemost. 79, 202-210.